Panacea Biotec and Consortium Launch DENSTAR Project to Advance Dengue Vaccine Licensure in Sub-Saharan Africa

Panacea Biotec and Consortium Launch DENSTAR Project to Advance Dengue Vaccine Licensure in Sub-Saharan Africa​

Panacea Biotec Limited has partnered with a global consortium to launch the DENSTAR project, a significant four-year initiative aimed at advancing the licensure and facilitating the global use of its tetravalent dengue vaccine, DengiAll®, specifically within sub-Saharan Africa (sSA). The project officially commenced on June 1, 2026.

The DENSTAR project is designed to reduce the burden of Neglected Tropical Diseases (NTDs), including dengue fever, across Africa by promoting equitable access to effective prevention tools. This initiative is funded under the Global Health European & Developing Countries Clinical Trials Partnership 3 Joint Undertaking (GH EDCTP3 JU) and is supported by the European Union.

The project is coordinated by the Sclavo Vaccines Association, a non-profit organization based in Siena, Italy, dedicated to supporting vaccine research and development in developing nations. Panacea Biotec serves as a key partner in this diverse consortium, having developed DengiAll®, a tetravalent dengue vaccine that targets all four virus serotypes and is currently in late-stage development in India.

Scientific Focus and Vaccine Advantages​

The DENSTAR consortium will conduct Phase 1/111 studies involving healthy adults and children in Africa to confirm the safety and effectiveness of the DengiAll® vaccine within this population, paving the way for regulatory approval and deployment in sSA.

A critical aspect of the project involves addressing knowledge gaps by evaluating vaccine efficacy against Dengue Virus serotype 4 (DENV-4) using Controlled Human Infection Models (CHIMs). This research is essential to strengthen scientific evidence and build public confidence regarding future widespread use of the vaccine.

The dengue vaccine offers several advantages for large scale deployment, particularly in low and middle income countries. Key features include being single dose, cost efficient to manufacture, and suitable for technology transfer. Unlike other existing vaccines, DengiAll® does not require prior serological testing, making it a practical solution for diverse populations and equitable immunization strategies.

The DENSTAR Consortium Details​

The DENSTAR consortium brings together 10 partners from 9 countries across Europe, Africa, the United States, India, and South Korea. These participants include universities, research organizations, biotech companies, and non-profit organizations, forming a public private partnership aimed at bridging critical gaps in dengue prevention.

The project aims to build locally led research capacity by supporting training opportunities for MPH and PhD students across participating institutions, while also strengthening the readiness of African study sites for high quality clinical trials.

Key details regarding the DENSTAR project and its participants are summarized below:


The consortium members include:

PANACEABIO Stock Price Movement​

Today, shares of Panacea Biotec Limited edged higher in post-market trading, closing at ₹552.90 after gaining 2.37% on a move of ₹12.80. The stock maintained interest throughout the day, with solid volume hitting 791,028 shares and price action ranging between a low of ₹525 and a high of ₹562.65.